TY - JOUR
T1 - The Impact of Clinical Setting on Evaluating Patients Using the PROMIS-29 Baseline Measures in the COVID Era
T2 - A Retrospective Multicenter Quantitative Analysis
AU - Engle, Alyson M.
AU - Abd-Elsayed, Alaa
AU - Pope, Jason E.
AU - Fishman, Michael
N1 - Funding Information:
The authors would like to thank Chris Hanes for his work in data management and statistical analysis. No funding or sponsorship was received for this study or publication of this article. The Rapid Service Fee was funded by the authors. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published. Alyson M. Engle—concept and design, statistical analysis, drafting and editing the manuscript. Alaa Abd-Elsayed—concept and design, statistical analysis, drafting and editing the manuscript. Jason E. Pope—concept and design, statistical analysis, drafting and editing the manuscript. Michael Fishman—concept and design, statistical analysis, drafting and editing the manuscript. Dr. Pope is a consultant for Abbott, Medtronic, Flowonix, Ethos, PainTEQ, Thermaquil, Vertos, Boston Scientific, Saluda, SpineThera, SPR Therapeutics, WISE, Stimgenics and Aurora Spine. He has equity in Stimgenics, SPR Therapeutics, SpineThera, Thermaquil, Vertos, Neural Integrative Solutions, AGR, PainTEQ, and Celéri Health, and his institution receives research grants from PainTEQ, Boston Scientific, Abbott, Medtronic, Saluda, Vertos, Ethos, Flowonix, and AIS. Dr. Fishman is a consultant to Abbott, Biotronik, Braeburn, CornerLoc, Medtronic, Thermaquil, and Nevro. His institution received research grants and payments from Abbott, Biotronik, Lumbrera, Medtronic, Stimgenics, Thermaquil, and Vertiflex. He has equity in Celéri Health and Thermaquil. Dr. Fishman’s spouse is an employee of Globus Medical. Dr. Engle has nothing to disclose. Dr. Abd-Elsayed is a consultant of Medtronic, Celéri Health and Avanos. At each participating institution, a waiver of consent and a full waiver of HIPAA authorization was obtained through the WIRB under Common Rule 45 CFR 46.116. The data sets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
Publisher Copyright:
© 2021, The Author(s).
PY - 2021/12
Y1 - 2021/12
N2 - Background: Multidimensional patient-reported outcomes are a critical part of assessing patients to better understand their well-being during treatment. The PROMIS-29 assessment tool is utilized as a component of assessing multidimensional pain scales. It includes patient-reported measures of pain, mood, sleep, social participation, and function. Currently, there are no data on whether a patient’s immediate environment (remote versus in person) influences the reported patient outcomes measurement of a multidimensional tool represented as PROMIS-29 data. Methods: Retrospective analysis of prospectively collected data was performed. Subjects were identified and consecutively enrolled upon entry into a chronic pain or spine center in the United States. The PROMIS-29 v2.1 was recorded. Statistical differences were assessed among age groups and across the seven domains of the assessment. Results: A total of 25,187 distinct patients were enrolled in the study from August 2018 to December 2020 with a presenting baseline measurement of PROMIS-29. The PROMIS-29 v2.1 was evaluated across the seven domains, and subgroup age analysis was performed for patients completing surveys in the clinical setting (non-remote group) and those completing the survey in the remote setting (remote group) during entry into spine and pain practices across the United States. For mental health scores, those less than 40 years of age and those over 80 years of age showed significant differences in ratings of anxiety and depression in the remote versus non-remote setting. Regarding physical health scores, those aged 60–79 showed a significant difference in the remote versus non-remote ratings for pain interference (p = 0.005; 63.9 vs. 64.4), physical function (p = 0.000; 36.4 vs. 35.7), and fatigue (p = 0.020; 57.2 vs. 57.7), while subjects over 80 years of age showed a statistical difference between the remote versus non-remote setting only in rating physical function (p = 0.025; 33.0 vs. 34). Notably, the rating of sleep disturbance in the remote versus non-remote setting was the only significant variable in the 40–59 age category (p = 0.000; 60.0 vs. 59.1). Those less than 40 years of age also reported a significant difference in the remote versus non-remote setting when rating sleep disturbance (p = 0.000; 60.5 vs. 58.9). With regard to social function, only those older than 80 years showed a significant difference in rating of ability in the remote compared to the non-remote setting (p = 0.031; 39.6 vs. 40.7). Conclusions: This data set is the first published data describing the influence of environment (remote versus in person) on PROMIS-29 outcome measurements in the chronic pain population.
AB - Background: Multidimensional patient-reported outcomes are a critical part of assessing patients to better understand their well-being during treatment. The PROMIS-29 assessment tool is utilized as a component of assessing multidimensional pain scales. It includes patient-reported measures of pain, mood, sleep, social participation, and function. Currently, there are no data on whether a patient’s immediate environment (remote versus in person) influences the reported patient outcomes measurement of a multidimensional tool represented as PROMIS-29 data. Methods: Retrospective analysis of prospectively collected data was performed. Subjects were identified and consecutively enrolled upon entry into a chronic pain or spine center in the United States. The PROMIS-29 v2.1 was recorded. Statistical differences were assessed among age groups and across the seven domains of the assessment. Results: A total of 25,187 distinct patients were enrolled in the study from August 2018 to December 2020 with a presenting baseline measurement of PROMIS-29. The PROMIS-29 v2.1 was evaluated across the seven domains, and subgroup age analysis was performed for patients completing surveys in the clinical setting (non-remote group) and those completing the survey in the remote setting (remote group) during entry into spine and pain practices across the United States. For mental health scores, those less than 40 years of age and those over 80 years of age showed significant differences in ratings of anxiety and depression in the remote versus non-remote setting. Regarding physical health scores, those aged 60–79 showed a significant difference in the remote versus non-remote ratings for pain interference (p = 0.005; 63.9 vs. 64.4), physical function (p = 0.000; 36.4 vs. 35.7), and fatigue (p = 0.020; 57.2 vs. 57.7), while subjects over 80 years of age showed a statistical difference between the remote versus non-remote setting only in rating physical function (p = 0.025; 33.0 vs. 34). Notably, the rating of sleep disturbance in the remote versus non-remote setting was the only significant variable in the 40–59 age category (p = 0.000; 60.0 vs. 59.1). Those less than 40 years of age also reported a significant difference in the remote versus non-remote setting when rating sleep disturbance (p = 0.000; 60.5 vs. 58.9). With regard to social function, only those older than 80 years showed a significant difference in rating of ability in the remote compared to the non-remote setting (p = 0.031; 39.6 vs. 40.7). Conclusions: This data set is the first published data describing the influence of environment (remote versus in person) on PROMIS-29 outcome measurements in the chronic pain population.
KW - Chronic pain
KW - PROs
KW - Patient-reported outcomes
KW - Remote assessments
UR - http://www.scopus.com/inward/record.url?scp=85116252778&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85116252778&partnerID=8YFLogxK
U2 - 10.1007/s40122-021-00323-3
DO - 10.1007/s40122-021-00323-3
M3 - Article
C2 - 34599754
AN - SCOPUS:85116252778
SN - 2193-8237
VL - 10
SP - 1663
EP - 1672
JO - Pain and Therapy
JF - Pain and Therapy
IS - 2
ER -